To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age of 18 and 65
Histologically confirmed colorectal cancer and two methords of imaging detection confirmed liver metastasis
Potentially curable by resection, as determined by a surgeon with hepatic surgery expertise
No evidence of extrahepatic disease by chest x-ray or CT scan of the chest, abdomen, and pelvis
Patients with adequate hepative, renal and bone marrow function
Signed written informed consent
You may not be if
Pregnant or nursing patients (fertile patients must use effective contraception)
Other malignancy within the past 5 years except completely resected nonmelanoma skin cancer or carcinoma in situ of the cervix
Preexisting grade 2 or greater peripheral neuropathy
Concurrent uncontrolled illness
Ongoing or active infection
Psychiatric illness or social situation that would preclude study compliance
Less than 6 months since prior adjuvant fluorouracil-based chemotherapy
Prior chemotherapy for liver metastasis
Prior oxaliplatin for colorectal cancer
Prior or concurrent hepatic artery infusion chemotherapy for metastatic disease
Prior or concurrent radiotherapy for metastatic disease
Prior or concurrent radiofrequency ablation for metastatic disease
concurrent treatment with any other anti-cancer therapy.
Clareo Health | Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)
